Insider trading

Period: 120 months Stock: EWTX Minimum amount: $100K × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

69 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

69 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

69 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

69 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
69 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
69 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

69 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
13 Aug 2026
Sold at will
$126.70K 2,919 at 43.41
25.3%
Not planned
12 Aug 2026
KOCH KEVIN President and CEO
Sold at will 3×
$785.04K 17,971 at 43.68
25.5%
Not planned
12 Aug 2026
Sold at will 4×
$286.00K 6,522 at 43.85
36.1%
Not planned
12 Aug 2026
Russell Alan J Chief Scientific Officer
Sold at will 3×
$258.04K 5,901 at 43.73
15.8%
Not planned
12 Aug 2026
Derakhshan Behrad Chief Business Officer
Sold at will 4×
$223.42K 5,100 at 43.81
13.8%
Not planned
12 Aug 2026
MOORE JOHN R General Counsel
Sold at will 4×
$219.82K 5,016 at 43.82
22.1%
Not planned
1 Jul 2026
Russell Alan J Chief Scientific Officer
Sold on a plan 2×
$7.88M 200,000 at 39.41
89.1%
Sold half or more
5 May 2026
Sold at will
$1.93M 50,000 at 38.57
92.0%
Sold half or more
4 May 2026
Sold at will
$163.66K 5,230 at 31.29
54.5%
Sold half or more
1 Apr 2026
Sold on a plan
$926.10K 28,662 at 32.31
74.9%
Sold half or more
31 Mar 2026
Sold on a plan
$685.31K 21,338 at 32.12
69.0%
Sold half or more
27 Mar 2026
Sold on a plan 2×
$506.73K 16,358 at 30.98
63.0%
Sold half or more
21 Jan 2026
Edris Badreddin Director
Sold on a plan 5×
$3.40M 115,471 at 29.44
85.4%
Sold half or more
12 Nov 2025
Russell Alan J Chief Scientific Officer
Sold at will
$2.11M 100,000 at 21.12
81.0%
Sold half or more
11 Nov 2025
Fox Jonathan C Director
Bought
$199.40K 10,700 at 18.64
82.3%
Largest buy in 3 yrs
26 Aug 2025
Russell Alan J Chief Scientific Officer
Sold at will
$1.46M 100,000 at 14.60
81.0%
Sold half or more
12 Aug 2025
KOCH KEVIN President and CEO
Sold at will
$106.76K 7,972 at 13.39
20.7%
Not planned
3 Apr 2025
ORBIMED ADVISORS LLC Director · indirect
Bought 2×
$10.00M 496,771 at 20.13
3.5%
Largest buy in 3 yrs
3 Apr 2025
Thompson Peter A. Director · indirect
Bought 2×
$10.00M 496,771 at 20.13
3.5%
Largest buy in 3 yrs
5 Feb 2025
Derakhshan Behrad Chief Business Officer
Sold at will
$300.30K 10,000 at 30.03
37.3%
Not planned
5 Feb 2025
KOCH KEVIN President and CEO
Sold on a plan
$259.30K 8,636 at 30.03
37.4%
Planned (10b5-1)
5 Feb 2025
Russell Alan J Chief Scientific Officer
Sold on a plan
$240.62K 8,015 at 30.02
35.0%
Planned (10b5-1)
28 Jan 2025
Sold on a plan
$690.66K 25,000 at 27.63
60.4%
Sold half or more
30 Dec 2024
Russell Alan J Chief Scientific Officer
Sold on a plan
$2.74M 100,000 at 27.37
87.1%
Sold half or more
24 Dec 2024
Semigran Marc Chief Development Officer
Sold on a plan 2×
$881.92K 29,709 at 29.69
81.6%
Sold half or more
23 Sep 2024
MOORE JOHN R General Counsel
Sold at will
$578.06K 20,922 at 27.63
86.5%
Sold half or more
20 Sep 2024
Carruthers R Michael Chief Financial Officer
Sold at will 4×
$3.57M 125,092 at 28.57
94.8%
Sold half or more
20 Sep 2024
Russell Alan J Chief Scientific Officer
Sold at will 2×
$2.12M 75,000 at 28.27
85.5%
Sold half or more
20 Sep 2024
MOORE JOHN R General Counsel
Sold at will
$1.42M 50,000 at 28.37
93.9%
Sold half or more
20 Sep 2024
Derakhshan Behrad Chief Business Officer
Sold at will
$1.22M 42,068 at 29.03
73.6%
Sold half or more
20 Sep 2024
Sold at will
$202.60K 7,162 at 28.29
33.0%
Not planned
9 Feb 2024
MOORE JOHN R General Counsel
Sold on a plan
$160.66K 8,029 at 20.01
100%
Sold half or more
7 Feb 2024
MOORE JOHN R General Counsel
Sold on a plan
$359.86K 17,993 at 20.00
100%
Sold half or more
23 Jan 2024
ORBIMED ADVISORS LLC Director · indirect
Bought
$5.00M 454,545 at 11.00
3.3%
23 Jan 2024
Thompson Peter A. Director · indirect
Bought
$5.00M 454,545 at 11.00
3.3%
23 Jan 2024
Carruthers R Michael Chief Financial Officer
Sold on a plan
$1.42M 90,000 at 15.78
75.6%
Sold half or more
26 Dec 2023
Russell Alan J Chief Scientific Officer
Sold at will
$1.61M 172,585 at 9.33
98.0%
Sold half or more
26 Dec 2023
Fox Jonathan C Director
Bought
$100.96K 10,857 at 9.30
opened
First buy on file
16 Sep 2022
ORBIMED ADVISORS LLC Director · indirect
Bought
$5.00M 484,496 at 10.32
3.6%
16 Sep 2022
Thompson Peter A. Director · indirect
Bought
$5.00M 484,496 at 10.32
3.6%
14 Sep 2022
Novo Holdings A/S 10% owner
Bought
$5.00M 484,496 at 10.32
8.7%
21 Jun 2022
MOORE JOHN R General Counsel
Sold, plan not stated
$226.70K 31,078 at 7.29
91.2%
Sold half or more
17 Jun 2022
MOORE JOHN R General Counsel
Sold, plan not stated
$146.43K 22,127 at 6.62
88.1%
Sold half or more
15 Jun 2022
MOORE JOHN R General Counsel
Sold, plan not stated 2×
$114.02K 18,660 at 6.11
86.1%
Sold half or more
7 Jun 2022
MOORE JOHN R General Counsel
Sold, plan not stated 2×
$119.70K 18,123 at 6.61
85.8%
Sold half or more
18 May 2022
Thompson Peter A. Director · indirect
Bought
$994.98K 138,000 at 7.21
1.0%
18 May 2022
ORBIMED ADVISORS LLC Director · indirect
Bought
$994.98K 138,000 at 7.21
1.0%
12 Nov 2021
Russell Alan J Chief Scientific Officer
Sold, plan not stated
$167.07K 8,562 at 19.51
94.7%
Sold half or more
11 Nov 2021
Russell Alan J Chief Scientific Officer
Sold, plan not stated 2×
$384.24K 19,276 at 19.93
68.1%
Sold half or more
10 Nov 2021
Russell Alan J Chief Scientific Officer
Sold, plan not stated 2×
$243.17K 12,326 at 19.73
30.3%
Showing 1–50 of 69. Page 1 of 2 Older →